Akari Therapeutics (NASDAQ:AKTX) Price Target Raised to $27.00 at HC Wainwright

Akari Therapeutics (NASDAQ:AKTX) had its price objective raised by HC Wainwright from $1.60 to $27.00 in a research note released on Wednesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages have also recently weighed in on AKTX. LADENBURG THALM/SH SH assumed coverage on Akari Therapeutics in a research report on Monday, January 5th. They issued a “buy” rating and a $40.00 price target for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Akari Therapeutics in a report on Wednesday, January 21st. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $89.00.

Akari Therapeutics Price Performance

Shares of NASDAQ:AKTX opened at $4.65 on Wednesday. Akari Therapeutics has a 12-month low of $4.45 and a 12-month high of $63.20. The firm has a fifty day moving average of $8.79 and a two-hundred day moving average of $17.84.

Akari Therapeutics (NASDAQ:AKTX) last released its quarterly earnings data on Monday, March 30th. The biopharmaceutical company reported ($2.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($2.65).

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Akari Therapeutics stock. Armistice Capital LLC acquired a new stake in shares of Akari Therapeutics PLC (NASDAQ:AKTX) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned about 5.95% of Akari Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 5.06% of the company’s stock.

Akari Therapeutics Company Profile

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.